

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

**CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): January 10, 2011

STEREOTAXIS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-50884

(Commission File Number)

94-3120386

(IRS Employer Identification No.)

4320 Forest Park Avenue, Suite 100, St. Louis, Missouri

(Address of Principal Executive Offices)

63108

(Zip Code)

(314) 678-6100

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure

On January 10, 2011, Stereotaxis, Inc. (the “Company”) issued a press release (the “Press Release”) announcing that Siemens Healthcare has been named a non-exclusive, reseller for Stereotaxis’ Odyssey™ Enterprise Cinema solutions. A copy of the Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.

Forward Looking Statements and Additional Information

Statements are made herein or incorporated herein that are “forward-looking statements” as defined by the Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical fact, included or incorporated herein that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are not guarantees of future events or the Company’s future performance and are subject to risks, uncertainties and other important factors that could cause events or the Company’s actual performance or achievements to be materially different than those projected by the Company. For a full discussion of these risks, uncertainties and factors, the Company encourages you to read its documents on file with the SEC. Except as required by law, the Company does not intend to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

The information furnished in this Item 7.01 (including the Press Release attached as Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. In addition, this report (including the Press Release attached as Exhibit 99.1) shall not be deemed an admission as to the materiality of any information contained herein that is required to be disclosed solely as a requirement of this Item.

Item 9.01. Financial Statements and Exhibits

Exhibits.

99.1 Stereotaxis, Inc. Press Release dated January 10, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEREOTAXIS, INC.

Date: January 10, 2011

By: /s/ Daniel J. Johnston

Name: Daniel J. Johnston

Title: Chief Financial Officer

EXHIBIT INDEX

99.1 Stereotaxis, Inc. Press Release dated January 10, 2011.



Company Contact:
Dan Johnston
Chief Financial Officer
314-678-6007

Investor Contact:
EVC Group, Inc.
Doug Sherk & Gregory Gin
415-896-6820

Media Contact:
EVC Group, Inc.
Steve DiMattia
646-201-5445

Stereotaxis Announces Siemens as Global Reseller for Odyssey™ Enterprise Cinema Solutions

ST. LOUIS, MO, January 10, 2011—Stereotaxis, Inc. (NASDAQ: STXS) announced today that Siemens Healthcare has been named a non-exclusive, reseller for Stereotaxis' Odyssey™ Enterprise Cinema solutions including its state-of-the-art Cinema and Interface products. These products are designed to significantly enhance patient care by enabling hospitals to remotely access integrated data from procedures throughout hospital networks and around the world.

Siemens will sell Odyssey Enterprise Cinema with an interface to its Siemens Artis zee® large display, delivering a real-time information management solution. The combined offering enables consolidated information from a Siemens Artis zee large display to be remotely viewed live or played back after procedures for a comprehensive case archive enhancing staff training and patient care. Cinema then transmits lab information via a global Odyssey Network to allow hospitals to efficiently share procedure data anywhere around the world for clinical collaboration and to drive patient referrals.

“We have been impressed by the significant industry support for the Odyssey portfolio,” said Michael P. Kaminski, Stereotaxis President and CEO. “This new Siemens reseller relationship represents the latest chapter for Odyssey in what continues to be a very exciting story. We believe Stereotaxis will benefit from the sales prowess of Siemens Healthcare with its expansive sales channels.”

Odyssey systems have been sold into 112 of the 2,500 world-wide Electrophysiology labs since its initial release. Additionally, Odyssey products have the potential to expand beyond Electrophysiology to include Interventional Cardiology departments with approximately 9,000 IC labs world-wide. New replacements of these labs represent a significant opportunity for Odyssey solutions with an increasing percentage of new labs being replaced by consolidated display solutions.

“Siemens continues to focus on delivering solutions that leverage the most advanced technologies available for addressing our customers’ needs,” said Robert Dewey, Senior Director, Cardiac and Hybrid OR X-ray Systems, Siemens AG Healthcare Sector. “Siemens sees the value of combining the features of technologies such as Stereotaxis’ Odyssey Enterprise Cinema products with the Siemens Artis zee large display to provide our customers with an outstanding solution that optimizes workflow and improves productivity.”

About Stereotaxis

www.stereotaxis.com

www.odysseyexperience.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe[®] Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis’ Odyssey[™] portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey[™] Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey[™] Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Odyssey[™] then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

About Siemens Healthcare

www.siemens.com/healthcare

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better

and more cost-effective. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2010 (to September 30), the Sector posted revenue of 12.4 billion euros and profit of around 750 million euros.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.